atumelnant
-
Crinetics Pharmaceuticals: PALSONIFY Business Update and Atumelnant Phase 2 Trial Topline Results for Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals will host an investor call on January 5th, 2026, to discuss PALSONIFY’s commercialization strategy and present topline Phase 2 data for atumelnant in congenital adrenal hyperplasia. Management will provide updates on their go-to-market plan for PALSONIFY and share results from the fourth cohort of the atumelnant trial, offering insights into the company’s pipeline and future prospects.
